Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
IMNM - Immunome, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$36.50
DETAILS
HIGH:
$40.00
LOW:
$33.00
MEDIAN:
$36.50
CONSENSUS:
$36.50
UPSIDE:
56.32%
Stock News
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company's 2024 In.
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's proprietary TOP1 inhibitor payload. “The first patient dosed with IM-1617 is a significant milestone for Immunom.
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's strong Phase 3 desmoid tumor data and an NDA submission. IMNM's cash position of $582.7M supports operations through 2028, enabling pipeline acceleration and mitigating near-term dilution risk. Varegacestat's efficacy (HR 0.16, ORR 56%) positions IMNM to challenge Ogsiveo in desmoid tumors, with broader TAM potential in ADCs and radioligand therapies.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company's 2024 Induc.
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed efficacy and safety results from RINGSIDE, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoid tumors. The data are being presented today in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual.
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webca.
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. “This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “The NDA submission for v.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 450,000 shares of common stock to nineteen new employees under the Company's 2024 Indu.
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. “The varegacestat NDA submission marks an important milestone for Immunome. It r.
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 2.
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company,
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.
Price Targets
Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage
$37.00
(was $22.11)
Supawat Thongthip
·
Truist Financial
Barclays Starts Immunome Inc. (IMNM) at Overweight
$36.00
(was $22.11)
Lukas Shumway
·
Barclays
Immunome price target lowered to $33 from $37 at Leerink
$33.00
(was $22.02)
Andrew Berens
·
Leerink Partners
Immunome initiated with a Buy at H.C. Wainwright
$40.00
(was $23.41)
H.C. Wainwright
Immunome price target raised to $32 from $22 at Lake Street
$32.00
(was $23.39)
Lake Street
Immunome price target raised to $40 from $18 at Evercore ISI
$40.00
(was $23.35)
Evercore ISI
Immunome price target raised to $40 from $38 at Leerink
$40.00
(was $22.65)
Leerink Partners
Immunome initiated with a Buy at Truist
$36.00
(was $18.42)
Karina Rabayeva
·
Truist Financial
Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login
$33.00
(was $17.14)
Stephens
Immunome initiated with a Buy at Craig-Hallum
$26.00
(was $10.52)
Craig-Hallum
Immunome initiated with an Outperform at Evercore ISI
$18.00
(was $10.30)
Evercore ISI
Immunome price target lowered to $23 from $27 at Piper Sandler
$23.00
(was $12.64)
Biren Amin
·
Piper Sandler
Immunome initiated with a Buy at Guggenheim
$35.00
(was $20.58)
Michael Schmidt
·
Guggenheim
Immunome price target raised to $33 from $27 at Wedbush
$33.00
(was $24.68)
David Nierengarten
·
Wedbush